1180 related articles for article (PubMed ID: 16809259)
1. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
2. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
3. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
4. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
6. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
7. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
[TBL] [Abstract][Full Text] [Related]
8. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
9. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
10. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
11. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
12. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
13. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
15. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
16. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
[TBL] [Abstract][Full Text] [Related]
17. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
Kawamura K
Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
[TBL] [Abstract][Full Text] [Related]
18. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
19. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
20. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
Greil S; Robinson EA; Singal B; Kleer E
Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
